News

ISRG nears a key support level after a 23.7% YTD drop, but strong da Vinci 5 adoption and procedure growth may fuel a rebound.

In recent months, Intuitive Surgical has faced FDA Class I recalls on certain da Vinci stapler components and visible institutional selling, reflecting elevated concern around product safety and regulatory scrutiny despite earlier strong quarterly results. These developments coincide with ongoing competition in surgical robotics and highlight how regulatory risk and large investor behavior can quickly influence perceptions of an otherwise growing, cash-generative business model. We’ll now...

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

The heavy selling pressure might have exhausted for Intuitive Surgical (ISRG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Many investors understandably have doubts about the company right now.

Intuitive Surgical (ISRG) is well positioned to outperform the market, as it exhibits above-average growth in financials.

The average brokerage recommendation (ABR) for Intuitive Surgical (ISRG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Wondering if Intuitive Surgical at around US$453 per share is still worth your attention, or if the stock price already reflects most of the opportunity? The stock has been relatively flat over the past week with a 0.9% decline and is roughly unchanged over 30 days. Year to date it is down 19.3%, the 1 year return sits at a 15.7% decline, and the 3 year and 5 year returns are 49.4% and 65.8% respectively. Recent share price moves come as investors continue to assess the company's position in...

Becton, Dickinson and Company (NYSE:BDX) reported fiscal second-quarter revenue and adjusted earnings ahead of its internal expectations, while management raised its full-year adjusted earnings outlook and said growth was broad-based across most of the portfolio. Chairman, Chief Executive Officer a

Intuitive Surgical's success hints that this competitor could have more growth potential than investors think.

Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the 8 Best Healthcare AI Stocks to Buy According to Analysts. On April 23, 2026, Barclays lowered its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $651 from $712 while maintaining an Overweight rating following the company’s Q1 results. The firm said the quarter delivered a “strong fundamental […]

R. Jeffrey Bailly: Thank you, Ron, and thank you to everyone joining the call. UFP had a strong second quarter. Revenue from our two largest customers, Intuitive Surgical and Stryker, grew 10% and 567%, respectively.

Why Intuitive Surgical stock is drawing attention now Intuitive Surgical (ISRG) is back in focus after a choppy stretch for the stock, prompting investors to reassess how its current share price lines up with recent returns and the scale of its surgical robotics business. See our latest analysis for Intuitive Surgical. At a share price of US$457.78, Intuitive Surgical has seen a 1-day share price return close to flat, a 7-day share price return of a 2.8% decline, and a year-to-date share...

Is ISRG a good stock to buy? We came across a bullish thesis on Intuitive Surgical, Inc. on Rijnberk InvestInsights’s Substack by Daan | InvestInsights. In this article, we will summarize the bulls’ thesis on ISRG. Intuitive Surgical, Inc.’s share was trading at $451.29 as of April 21st. ISRG’s trailing and forward P/E were 59.16 and 46.51 […]

Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. A caller asked for Cramer’s thoughts on the company, and he said: Here’s the thing: Both J&J and Medtronic claim they’ve got competitors. And I am worried that one of those two is going to hit […]

Intuitive Surgical makes surgical robots, but that's not how it makes most of its money.

These longtime market beaters may not have peaked yet.

Intuitive Surgical (NASDAQ:ISRG) stockholders voted to approve all four proposals presented at the company’s 2026 Annual Meeting of Stockholders, which was held virtually, according to meeting remarks led by Gary Loeb, executive vice president and chief legal and compliance officer. Annual meeting

Intuitive Surgical faces mixed international trends as China pressure and Japan delays cloud otherwise strong OUS growth outlook.

Intuitive Surgical’s first quarter results for 2026 exceeded Wall Street’s expectations, with management crediting the outcome to strong global procedure growth and expansion of the da Vinci and Ion platforms. CEO David Rosa pointed to a 17% increase in total procedures, including “broad-based adoption across da Vinci and Ion as customers continue to advance minimally invasive care.” The company also highlighted notable gains in after-hours and non-urology procedures, as well as expanding uptake

Intuitive Surgical recently reported past first-quarter 2026 results showing revenue of US$2,770.8 million and net income of US$821.5 million, alongside completing a multi-year buyback of 29,440,210 shares for US$9.08 billion. The combination of higher earnings per share and a reduced share count from the long-running repurchase program highlights management’s focus on reinforcing shareholder value through both operating performance and capital allocation. We’ll now examine how this stronger...

Robotic surgery’s market leader has had a rough start to 2026, but our model sees the pullback as an opportunity. Intuitive Surgical (NASDAQ:ISRG) trades at $482.22 after a 14.86% year-to-date decline, even as Q1 procedure growth and da Vinci 5 adoption continue to accelerate. Our 24/7 Wall St. price target for Intuitive Surgical is $615.93, ... Why Intuitive Surgical Is a Strong Buy as Robotic Surgery Adoption Accelerates

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Intuitive Surgical's strong Q1 results, rising procedures, and raised outlook highlight accelerating growth, while Boston Scientific faces headwinds and tempered guidance.

Intuitive Surgical (ISRG) possesses solid growth attributes, which could help it handily outperform the market.